Summit Therapeutics appoints David Roblin as COO
Dr. Roblin held senior leadership roles at Pfizer and Bayer where he was involved in research, development and commercialisation.
At Pfizer, he was Head of Research, Site Director and CMO for Europe R&D and he and his units were responsible for the development of several important and successful medicines.
At Bayer, Dr. Roblin was Head of Therapy Area for Anti-infectives where he was involved in the successful development of a number of antibiotics, including Avelox(TM) and Cipro(TM).
In 2014 Dr. Roblin was appointed COO and Director of Scientific Translation at the Francis Crick Institute in London where he led on establishing the operations of a new biomedical research institute at a purpose built state-of-the-art research facility in central London.
On stepping down from his full-time roles, Dr. Roblin will become a Senior Scientific Translation Fellow and Chair of the Translation Advisory Group at the Francis Crick Institute.
Dr. Roblin has been Chief Medical Officer and a Non-Executive Director to a number of biotech companies. He also serves on the Major Awards Committee of the Biomedical Catalyst Fund and of the Confidence in Concept and Proximity to Discovery of Medical Research Council. He also serves on the LEO Foundation Prize Committee.
Dr. Roblin has a degree in biochemistry from University College London and later qualified in medicine from St George's Hospital. He is a Fellow of the Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine.
Dr. Roblin is an honorary Professor of Medicine at Swansea University and Professor of Translational Medicine at St George's. He is a Board Director of MedCity and Destiny Pharma. Before entering the life sciences industry, he practised medicine for five years.